PICOPLUS® 1.8 GW Picosecond Laser

LUTRONIC Announces U.S. FDA Clearance for 1.8 GW Picosecond Laser

Lutronic, a world-leading developer and manufacturer of aesthetic and medical laser systems, announces clearance from the U.S. Food and Drug Administration (FDA) for the PICOPLUS® system. After hundreds have been sold internationally, the system is now available in the United States.

The PicoPlus platform offers both pico- and nanosecond modes with the power needed to address even difficult-to-treat cases that are resistant to other Nd:YAG systems. The system provides precise control over pulse-width, wavelength and fluence needed for outstanding results patients want, all from one premium platform.

“The PicoPlus system offers many benefits, including pigment removal, rejuvenation* and laser facial toning. The user interface is very friendly and comes with a toggle function for adjusting fluence energy settings very easily. Settings can be adjusted at any stage of treatment and the warmup time is very quick.” Dr. Saleem Loghdey, Australia.

The PicoPlus was cleared by the FDA to treat a variety of pigmented lesions and difficult tattoo cases. Its novel design, ergonomics, and exceptional precision and reliability have been demonstrated and highly valued around the world. Now this advanced picosecond and nanosecond platform can safely and effectively help U.S. practices achieve mastery over difficult pigment and tattoo cases.

About LUTRONIC

Lutronic, a leading innovator in advanced aesthetic and medical laser and related technology, was established in 1997 to bring intuitive, robust, versatile devices that are affordable and efficacious to the worldwide medical community. Committed to improving medicine, Lutronic partners with key opinion leaders to advance science and ensure the efficacy of its systems. All systems are versatile and offer multiple settings and options for customized treatments, which optimize outcomes for a wide variety of conditions in the fields of aesthetics, orthopedics, spinal surgery and ophthalmology.

With a focus on physician needs and patient outcomes, Lutronic dedicates time and funding toward the development of devices that offer features and improvements not found in today’s market. Devoting more than 20 percent of revenues to R&D, Lutronic holds more than 300 current and pending patents worldwide. With Lutronic Global located in the Boston area, Lutronic also has a major manufacturing office in Korea, offices in Germany, China and Japan and a worldwide network of direct sales teams and distributors that is ever expanding.

*Not an US FDA cleared indication

Contact Info: [email protected]